11/14/2024 | Press release | Distributed by Public on 11/14/2024 06:51
Safety and Efficacy of Pemivibart, a Long Acting Monoclonal Antibody, for Prevention of Symptomatic COVID 19: Interim Results From the CANOPY Clinical TrialCameron R. Wolfe et[...]
